Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024)
Nuvalent (NUVL) reported Other Accumulated Expenses of $1.3 million for Q4 2024, down 21.37% on a YoY basis from $1.6 million in Q1 2024, and down 21.37% quarter-over-quarter from $1.6 million in Q4 2023.
Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024) Analysis & Trends
Nuvalent has reported Other Accumulated Expenses for 2 years, with the latest figure at $1.3 million in Q4 2024.
- For the quarter ending Q4 2024, Other Accumulated Expenses fell 21.37% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2024 stood at $1.3 million (down 21.37% YoY), and the FY2024 full-year result was $1.3 million, down 21.37% from the prior year.
- Other Accumulated Expenses for Q4 2024 stood at $1.3 million, down from $1.6 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $1.6 million in Q4 2023, with the low at $1.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.62 Mn |